drugset / Trial / NCT06839560
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
RandomizedParallel-groupOpen-labelTreatment
Summary
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with advanced HER2-negative breast cancer with brain metastasis
Timeline
- Start
- 2025-03-01
- Primary completion
- 2028-09-10
- Completion
- 2028-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Capecitabine | Small molecule | 500 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Subject | Vinorelbine | Small molecule | 20 mg | Oral |